Literature DB >> 3263553

The distribution and clearance of radiolabeled human interleukin-1 beta in mice.

R C Newton1, J Uhl, M Covington, O Back.   

Abstract

Mice were injected with radiolabeled human interleukin-1 beta (IL-1) and monitored for tissue localization and route of clearance. IL-1 was labeled with no apparent loss of in vitro biological activity. Mice were injected by intravenous (i.v.), intraperitoneal (i.p.), and subcutaneous (s.c.) routes with either low dose (10 ng radiolabeled) or high dose (10 ng radiolabeled with 10 micrograms unlabeled) IL-1. Blood and urine were monitored and various tissues were counted for radioactivity after 2, 24 or 48 hours. Injection of either dose of IL-1 by i.v. route demonstrates a rapid initial loss of IL-1 from the circulation followed by a slower loss over the next hour. Injection by i.p. or s.c. routes gives an initial peak in circulating IL-1 after 10 minutes which is sustained over at least the next 7 hours with the high dose. Circulating IL-1 is associated with the plasma fraction and is not cell associated. Two hours after injection, most tissues examined were found to contain an equal amount of IL-1 on a weight basis with the exception of bone, which contains half the level found in other tissues, and kidney, which contains 4-8 fold more IL-1. The major route of clearance is the kidney with 10-20% of label found in the urine within hours of injection. IL-1 found in the urine contains intact 17 kD IL-1.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3263553

Source DB:  PubMed          Journal:  Lymphokine Res        ISSN: 0277-6766


  8 in total

1.  Tamm-Horsfall protein regulates circulating and renal cytokines by affecting glomerular filtration rate and acting as a urinary cytokine trap.

Authors:  Yan Liu; Tarek M El-Achkar; Xue-Ru Wu
Journal:  J Biol Chem       Date:  2012-03-27       Impact factor: 5.157

2.  IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation.

Authors:  Shlomo Z Ben-Sasson; Jane Hu-Li; Juan Quiel; Stephane Cauchetaux; Maya Ratner; Ilana Shapira; Charles A Dinarello; William E Paul
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-09       Impact factor: 11.205

3.  Synthesis and biological activities in vitro and in vivo of glycosylated human interleukin-1alpha, neoglyco IL-1alpha, coupled with N -acetylneuraminyl-galactose.

Authors:  Masaaki Ootsubo; Taku Chiba; Yutaka Kobayashi; Hidetoshi Hayashi; Akiko Hayashi; Kikuo Onozaki
Journal:  Glycoconj J       Date:  2004       Impact factor: 2.916

Review 4.  Interleukins. Clinical pharmacokinetics and practical implications.

Authors:  V Bocci
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

5.  Specific targeting of infectious foci with radioiodinated human recombinant interleukin-1 in an experimental model.

Authors:  C J van der Laken; O C Boerman; W J Oyen; M T van de Ven; R A Claessens; J W van der Meer; F H Corstens
Journal:  Eur J Nucl Med       Date:  1995-11

Review 6.  Tamm-Horsfall Protein is a Potent Immunomodulatory Molecule and a Disease Biomarker in the Urinary System.

Authors:  Tsai-Hung Wu; Ko-Jen Li; Chia-Li Yu; Chang-Youh Tsai
Journal:  Molecules       Date:  2018-01-22       Impact factor: 4.411

7.  Glycosylated human interleukin-1alpha, neoglyco IL-1alpha, coupled with N-acetylneuraminic acid exhibits selective activities in vivo and altered tissue distribution.

Authors:  S Sasayama; K Moriya; T Chiba; T Matsumura; H Hayashi; A Hayashi; K Onozaki
Journal:  Glycoconj J       Date:  2000-06       Impact factor: 2.916

8.  Changes in Mobility of the Golden Hamster with Induction of an IL-1-Induced Arthritis.

Authors:  I G Otterness; M L Bliven; A J Milici
Journal:  Mediators Inflamm       Date:  1994       Impact factor: 4.711

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.